Other

Stella Pharma Corporation

Kawakami, Koji

Oumi Nakajima

Koji Kawakami

Tomohisa Horibe

Masayuki Kohno

Mari Haramoto

Liying Yang

It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.

Selective anticancer chimeric peptides which bind neuropilin receptor

Selective anticancer chimeric peptides which bind transferrin receptor

Selective anticancer chimeric peptide comprising an EGF receptor-binding peptide and a cytotoxic peptide

Growing community of inventors

Kyoto, Japan

Oumi Nakajima